Lifestyle changes followed by bariatric surgery lower inflammatory markers and the cardiovascular risk factors C3 and C4

Metabolic Syndrome and Related Disorders

Volumn 13, Issue 1, 2015, Pages 29-35

  Nestvold, Torunn Kristin ^a,b   Nielsen, Erik Waage ^a,b,c   Ludviksen, Judith Krey ^a   Fure, Hilde ^a   Landsem, Anne ^a   Lappegård, Knut Tore ^a,b  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c NORD UNIVERSITY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; D DIMER; FIBRINOGEN; GAMMA INTERFERON; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 13; INTERLEUKIN 6; LEPTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ANTHROPOMETRY; ARTICLE; BARIATRIC SURGERY; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; HOSPITAL ADMISSION; HUMAN; INFLAMMATION; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; BLOOD; CARDIOVASCULAR DISEASES; CONTROLLED CLINICAL TRIAL; LIFESTYLE; METABOLISM; MIDDLE AGED; OBESITY, MORBID; RISK FACTOR; RISK REDUCTION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BARIATRIC SURGERY; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COMPLEMENT C3; COMPLEMENT C4; FEMALE; HUMANS; INFLAMMATION; LIFE STYLE; MALE; MIDDLE AGED; OBESITY, MORBID; RISK FACTORS; RISK REDUCTION BEHAVIOR; YOUNG ADULT;

EID: 84921508956     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2014.0099     Document Type: Article

References (44)

1. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: A systematic review and meta-analysis. JAMA 2004; 292:1724-1737.
2. Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide 2008. Obes Surg 2009;19:1605-1611.
3. Bastien M, Poirier P, Lemieux I, et al. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis 2014;56:369-381.
4. Bays HE, Gonzalez-Campoy JM, Bray GA, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008;6:343-368.
5. Troseid M, Nestvold TK, Rudi K, et al. Plasma lipopolysaccharide is closely associated with glycemic control and abdominal obesity: Evidence from bariatric surgery. Diabetes Care 2013;36:3627-3632.
6. Wang B, Li Q, Jiang Y, et al. Serum complement C3 has a stronger association with insulin resistance than high sensitive C-reactive protein in non-diabetic Chinese. Inflamm Res 2011;60:63-68.
7. Lappegard KT, Garred P, Jonasson L, et al. A vital role for complement in heart disease. Mol Immunol 2014;61:126-134.
8. Engstrom G, Hedblad B, Janzon L, et al. Complement C3 and C4 in plasma and incidence of myocardial infarction and stroke: A population-based cohort study. Eur J Cardiovasc Prev Rehabil 2007;14:392-397.
9. Engstrom G, Hedblad B, Eriksson KF, et al. Complement C3 is a risk factor for the development of diabetes: A population-based cohort study. Diabetes 2005;54:570-575.
10. Engstrom G, Hedblad B, Janzon L, et al. Weight gain in relation to plasma levels of complement factor 3: Results from a population-based cohort study. Diabetologia 2005; 48:2525-2531.
11. Palikhe A, Sinisalo J, Seppanen M, et al. Serum complement C3/C4 ratio, a novel marker for recurrent cardiovascular events. Am J Cardiol 2007;99:890-895.
12. Nilsson B, Hamad OA, Ahlstrom H, et al. C3 And C4 are strongly related to adipose tissue variables and cardiovascular risk factors. Eur J Clin Invest 2014;44:587-596.
13. Choy LN, Rosen BS, Spiegelman BM. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem 1992;267:12736-12741.
14. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006;17:4-12.
15. Gerner RR, Wieser V, Moschen AR, et al. Metabolic inflammation: Role of cytokines in the crosstalk between adipose tissue and liver. Can J Physiol Pharmacol 2013;91: 867-872.
16. Moschen AR, Molnar C, Geiger S, et al. Anti-inflammatory effects of excessive weight loss: Potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 2010;59:1259-1264.
17. Fain JN. Release of inflammatory mediators by human adipose tissue is enhanced in obesity and primarily by the nonfat cells: A review. Mediators Inflamm 2010;2010: 513948.
18. Fain JN, Tagele BM, Cheema P, et al. Release of 12 adipokines by adipose tissue, nonfat cells, and fat cells from obese women. Obesity (Silver Spring) 2010;18:890-896.
19. Fernandez-Real JM, Pickup JC. Innate immunity, insulin resistance and type 2 diabetes. Diabetologia 2012;55:273-278.
20. Nestvold TK, Nielsen EW, Lappegard KT. Bariatric surgery reduces risk factors for development of type 2 diabetes mellitus in morbidly obese, nondiabetic patients. Metab Syndr Relat Disord 2013;11:441-446.
21. Buchwald H. Consensus conference statement bariatric surgery for morbid obesity: Health implications for patients, health professionals, and third-party payers. Surg Obes Relat Dis 2005;1:371-381.
22. Hertle E, van Greevenbroek MM, Stehouwer CD. Complement C3: An emerging risk factor in cardiometabolic disease. Diabetologia 2012;55:881-884.
23. Brethauer SA, Heneghan HM, Eldar S, et al. Early effects of gastric bypass on endothelial function, inflammation, and cardiovascular risk in obese patients. Surg Endosc 2011;25:2650-2659.
24. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med 2014;370:2002-2013.
25. Appachi S, Kashyap SR. 'Adiposopathy' and cardiovascular disease: The benefits of bariatric surgery. Curr Opin Cardiol 2013;28:540-546.
26. Appachi S, Kelly KR, Schauer PR, et al. Reduced cardiovascular risk following bariatric surgeries is related to a partial recovery from "adiposopathy." Obes Surg 2011;21:1928-1936.
27. Kaptoge S, Seshasai SR, Gao P, et al. Inflammatory cytokines and risk of coronary heart disease: New prospective study and updated meta-analysis. Eur Heart J 2014;35:578-589.
28. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-2693.
29. Delling L, Karason K, Olbers T, et al. Feasibility of bariatric surgery as a strategy for secondary prevention in cardiovascular disease: a report from the Swedish obese subjects trial. J Obes 2010;2010.
30. Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA 2012;308: 1122-1131.
31. Sjostrom L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012;307: 56-65.
32. De PG, Tartagni M, Bartolomeo N, et al. Possible direct influence of complement 3 in decreasing insulin sensitvity in a cohort of overweight and obese subjects. Endocr Metab Immune Disord Drug Targets 2013;13:301-305.
33. Sakcak I, Avsar MF, Hamamci EO, et al. Comparison of early and late changes in immunoglobulins and acute phase reactants after laparoscopic adjustable gastric banding in patients with morbid obesity. Obes Surg 2010;20:610-615.
34. Dawson AJ, Sathyapalan T, Sedman P, et al. Insulin resistance and cardiovascular risk marker evaluation in morbid obesity 12 months after bariatric surgery compared to weight-matched controls. Obes Surg 2014;24:349-358.
35. Kopp HP, Kopp CW, Festa A, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 2003;23:1042-1047.
36. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013;13: 34-45.
37. Correia ML, Haynes WG. A role for plasminogen activator inhibitor-1 in obesity: From pie to PAI? Arterioscler Thromb Vasc Biol. 2006;26:2183-2185.
38. Alessi MC, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol 2007;18:240-245.
39. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: Links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006;26:2200-2207.
40. De TB, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: A common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 2005;5: 149-154.
41. Schalkwijk CG, Stehouwer CD. PAI-1 inhibition in obesity and the metabolic syndrome: A promising therapeutic strategy. Thromb Haemost 2006;96:698-699.
42. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med 2012;367:695-704.
43. Yu JH, Kim MS. Molecular mechanisms of appetite regulation. Diabetes Metab J 2012;36:391-398.
44. Sahu A. Intracellular leptin-signaling pathways in hypothalamic neurons: The emerging role of phosphatidylinositol-3 kinase-phosphodiesterase-3B-cAMP pathway. Neuroendocrinology 2011;93:201-210.